top of page

Search Results

Results found for "Dongbo Bu"

  • The One Reason Why Biotech Startups Fail More Often Than They Should

    . 👉 The company becomes busy instead of deliberate. The organization stays busy, but learning slows down. 👉 This pattern usually shows up in a very specific Strategy creates a shared filter that connects science execution and business reality. ✅ At its core, It has to be built deliberately and revisited continuously. or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building

  • Why Biotech Fundraising Fails Due to Intellectual Property Gaps

    built . being built This is the most frequent issue investors encounter. In biotech fundraising, coherence builds trust. It fails when intellectual property does not clearly support the business being built.   When science, intellectual property, and business intent reinforce each other, trust builds early and

  • The Hidden Operating Cadence That’s Actually Driving Your Biotech

    early-stage biotechs show the same pattern: strong scientific progress paired with an operating cadence built narrative checkpoints, and predictable timeline discipline, the organization typically shifts from “busy Decisions are made once and communicated clearly. 2️⃣ Cadence of Communication: The Rhythm That Builds Teams optimize for activity, not momentum Scientific surprises hit harder because the system has no buffer or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building

  • GPCR Binding Affinity Experiments: Interpreting Data With Confidence as We Head Into 2026

    in-depth lessons and 3 live AMAs  spanning binding, kinetics, efficacy, mechanism, and experimental design—built The strongest discovery programs aren’t built on instrumentation alone—they’re built on interpretation

  • Scientific Isolation: The Real Reason Early Biotechs Lose Traction

    . 👉 The uncomfortable truth: your company is doing a lot of science and very little building. Clear structure gives your science the visibility and consistency that traction is built on. Meetings end with explanations, not decisions BD calls “went great,” but nothing moves Timelines are built The danger is subtle: 👉Scientific isolation feels busy, intelligent, respectable. , or simply feeling stuck, this session will get you unstuck, fast. 👉 Book a 1:1 consult and start building

  • Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls

    Built for pharmacologists strengthening fundamentals, program teams navigating bottlenecks, and leaders

  • Asking Better Questions in Science: A Practical Guide for Emerging Researchers

    asking better questions in science, not as a skill you’re born with, but one you can intentionally build Building a Scientific Career Through Asking Better Questions in Science Late in the conversation, JB The scientist who asks the best questions builds the strongest network—and the most resilient expertise

  • When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue

    They exchanged instincts as much as data, and built a shared rhythm of problem-solving.

  • FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem

    Reverse Engineering Your Path to FDA Approval Most biotech development plans are built forward : start It's the test of how well you built it. Building FDA-Ready Thinking into Your Strategy Regulatory success is not a function. If you can’t see them too, you’re not building strategy, you’re building surprises. Because by the time they do, your timelines will stretch, your budgets will strain, and your confidence

  • Using Live-cell High-Content Screening to Characterize CB2 Ligands: Insights From 16 Synthetic Cannabinoids

    observed at higher concentrations, consistent with competitive displacement  These visual layers act as built-in

  • How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology

    What followed — a trip to London, confocal imaging marathons, and a partnership built on trust and curiosity Together, they built the first generation of GLP-1R fluorescent ligands — probes precise enough to visualize To build tools that performed consistently, JB and collaborators shifted toward a more rigorous parallelized chemists, theorists, biochemists, toxicologists, and cell biologists — all working toward the same goal: building

  • How System-Level GPCR Thinking Prevents Discovery Failures

    But HCS only works when assays are built with rigor and powered by the right fluorescent ligands. It’s a system-aware resource built for researchers who need clarity fast—reinforcing system-level GPCR

  • How to Avoid the Most Common Gaps in Your Biotech Pitch

    . ✅ Start with relevance, not results. 2️⃣ Using buzzwords instead of clarity Words like “platform”, It’s about strategic clarity. ✅ When your pitch follows this logic, it respects the listener’s time, builds It communicates that you know who you’re building for, why now is the right time, and how your solution , or simply feeling stuck, this session will get you unstuck, fast. 👉 Book a 1:1 consult and start building

  • GPCR Pharmacology Insights That Prevent Real Drug Discovery Failures

    They fail because a molecule behaved exactly as the underlying system allowed—amplified, buffered, redirected utility emerged from the interplay between β₁-mediated inotropy and α-mediated vascular effects that buffered

  • How Collaboration Drives GPCR Discoveries

    The future of discovery will belong to scientists who know how to build the right partnerships and stay Instead of forcing antibodies to do what they weren’t built for, JB’s group engineered fluorescent ligands when the cryo-EM data arrived — a structure solved through the same collaborative network that had built It’s about trust — the kind of trust built when collaborators confirm your data, replicate your results Here’s where the biggest opportunities will emerge: Building receptor-specific delivery systems for gene

  • High-Content Screening for GPCR Programs: Overcoming Assay Limitations with Fluorescent Ligands

    Key limitations of radioligand assays include:  • No spatial information  — signals are measured in bulk

  • How a Failed Experiment Created a Powerful GPCR Imaging Tool

    The literature was buzzing. Labs were competing.

  • From Farm Fields to GPCR Discovery, GLP-1 and GIP

    Meanwhile, researchers in the building across the way turned off the lights at 6 PM.

  • Decoding Schild Analysis: The Pharmacologist’s Lens on Competitive Antagonism

    Schild analysis turns receptor pharmacology into detective work, spotlighting mechanistic fingerprints buried Built for pharmacologists refining tools, discovery teams solving bottlenecks, and leaders seeking credible

  • How Schild Analysis Protects Your Conclusions in GPCR Research

    Listen to the episode ➤ Quick Links Assess GPCR Biased Signaling of Agonist How GPCR Collaboration Built

  • From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations

    Your scientific thinking built the foundation, but leadership is what scales it. waiting too long for certainty can destroy your momentum . 👉 Biotech founders often delay critical business But in business, decisions must be made under uncertainty . Clarity doesn’t precede action; it follows it.   2️⃣ “Eliminate error at all costs” Labs are built around or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start building

  • From Pipettes to Platforms: The Evolution of GPCR Research

    That’s not a story about nostalgia — it’s a snapshot of how GPCR research was built, on technique at of GPCR research today — from high-throughput ligand screens to real-time signaling readouts — are built The Evolution of GPCR Research Every generation of GPCR scientists inherits the tools of the last and builds What started as hand-built assays on ice has become integrated platforms for drug discovery, systems

  • How GPCR Spatial Signaling Sparked a Scientific Journey

    For innovators building tools, platforms, or therapeutics, these origin moments are where tomorrow’s She built on chance moments with deliberate moves—grants pursued, labs chosen, collaborations built. Built to Inspire The story of Michelle Halls isn’t just about a career; it’s about a pattern.

  • Molecular creativity in drug discovery

    . • Training Builds Innovation : Her lab model at Monash is shaping the next generation of GPCR scientists . 👉 Dive into spatial pharmacology ➤ A Note From Yamina: Building the Next Chapter of Dr.

  • Chemical Drug Matter : Rethinking the Molecules We Choose to Develop In Drug Discovery

    Building on Known Pharmacology Medicinal chemists learned early that modifying endogenous molecules — Why Terry’s Corner Terry’s Corner is a continuously growing knowledge platform built for scientists

  • GPCR Collaboration: From Models to Medicine

    From Lone Modeler to Collaborative Architect Carlsson’s lab is built to plug directly into a larger ecosystem Experimentalists often hesitate to rely on computational predictions, especially when burned in the past Over time, that transparency has built enduring partnerships , including one of Carlsson’s earliest with It’s built on trust between scientists. GPCR Podcast 🌱 Build a career with purpose, not just papers The Dr.

  • Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox

    Watch Episode 175 If your model can’t predict the future of GPCR drug discovery, why build it at all? For dopamine receptor studies, they built predictive models before experimental structures were available But success depends on researchers who can manage expectations, build trust, and integrate across disciplines Jens Carlsson breaks down the tools, challenges, and mindset behind building models that don’t just explain—they

  • Accelerating GPCR Drug Discovery: What 40 Years of Pharmacology Reveal

    That’s exactly what Terry’s Corner  was built to do: bring four decades of frontline discovery insight Every misaligned study is not just wasted budget—it’s lost time. Program Kill vs. It’s less bureaucratic than most outsiders think.

  • From Failed Experiments to Predictive GPCR Models

    a growing pharmacological interest, GPCRs presented the perfect challenge for someone who wanted to build

  • Irreversible Drugs, Real Control: Design for Durable Target Engagement

    Your Membership Gives You: Proven frameworks used in real discovery programs On-demand lessons built

bottom of page